Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
New to Comunitee?

or Sign Up with Email



FEB 13, 2013 - Yahoo! News

A Must Read - Share

After failed trials, J&J pivots to early-stage Alzheimer's

CHICAGO (Reuters) - A little over a year ago, Dr. Husseini Manji, global head of neuroscience drug development at Johnson & Johnson, predicted that brain researchers were on the cusp of a golden age. That was before J&J's highly anticipated Alzheimer's drug, bapineuzumab, failed to improve memory and thinking skills in closely watched clinical trials of people with mild to moderate forms of the disease. Had it worked, the drug would have been the first to alter the course of Alzheimer's, a fatal brain-wasting disease that affects 36 million people worldwide. ...

Tags: After failed trials, J&J pivots to early-stage Alzheimer's,  Alzheimer's Disease Latest News